CJC-1295 With DAC

CJC-1295 with DAC is a modified hGRF-derived peptide with a terminal maleimide-bearing lysine designed for albumin conjugation.

Identity

Sequence

H-Y[D-Ala]DAIFTQSYRKVLAQLSARKLLQDILSR[K(MPA)]-NH2

Residues

30

Molecular formula

C₁₆₅H₂₆₉N₄₇O₄₆

Average molecular weight

3647.2 g/mol

Monoisotopic mass (calculated)

3645.0155 Da

CAS number

446262-90-4

PubChem CID

91971820

Other names

CJC-1295 · CJC 1295

MPA is the maleimide-bearing group on added Lys30; its diagram token is schematic. Values describe the free peptide before albumin conjugation, without the paper’s trifluoroacetate counterion. PubChem lists 863288-34-0 as deprecated CAS. No separate UniProt identity was verified; the annotated sequence represents the structure without atom coordinates, SMILES or blend components.

Identity data from: PubChem CID 91971820 · Jetté et al., Endocrinology 2005, synthetic peptides and Figure 1

Research overview

CJC-1295 with DAC is derived from hGRF(1-29), a fragment of the hypothalamic peptide GHRH. Its peptide backbone includes D-Ala2, Gln8, Ala15 and Leu27, followed by an added lysine carrying a maleimide group. The original study describes the C-terminal extension as an Nε-3-maleimidopropionamide derivative of lysine. This reactive appendage distinguishes the DAC molecule from the corresponding backbone without that extension [1].

The maleimide group permits covalent bioconjugation to the free thiol at albumin Cys34. Jetté and colleagues examined preformed albumin conjugates in a DPP-IV stability assay and a secretion assay using cultured rat anterior pituitary cells. They also investigated the peptide in Sprague-Dawley rats and identified an immunoreactive species associated with the albumin band in plasma. These experiments concern the albumin-binding molecular form and the GHRH receptor research system [1].

Two randomised, placebo-controlled, double-blind studies were subsequently reported in healthy adults aged 21-61 years. Their design included pharmacokinetic measurements and endocrine sampling; they constitute a reported clinical-study context alongside the cell and rat experiments. The publication does not make the unconjugated backbone and the albumin-bound species identical experimental materials. Molecular form, reactive extension and assay context remain essential when interpreting the cited literature [2].

Laboratory storage and handling

Store sealed peptide vials under the temperature conditions stated in the lot documentation, protected from light and moisture. Let a cold vial reach room temperature before opening to limit condensation. Avoid repeated freezing and thawing of laboratory stocks, record storage history and the lot identifier, and use standard laboratory protective equipment. Chemical modifications and counterions should be checked against the supplied analytical description.

Questions about CJC-1295 with DAC

References

1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669
2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. PMID 16352683

Identity data checked on 2026-10-03. Literature summaries describe published research models and are not specifications of any product lot.